medigraphic.com
ISSN 0016-3813 (Print)

2013, Number 4

<< Back Next >>

Gac Med Mex 2013; 149 (4)

Hemophagocytic syndrome. Current concepts

Espinosa BKA, Garciadiego FP, León RE

Language: Spanish
References: 41
Page: 431-457
PDF size: 97.56 Kb.


ABSTRACT

Hemophagocytic lymphohistiocytosis is a syndrome characterized by pathological immune activation that may occur as either a primary a familial disorder (associated with genetic mutations), or as a sporadic condition, associated to infections, malignancies or autoimmune diseases. The clinical picture is characterized by a disproportionate inflammation that causes fever, cytopenias, splenomegaly, bone marrow hemophagocytosis, hypertriglyceridemia and hypofibrinogenemia. Syndrome-related mortality is high, so it is important to maintain a high index of suspicion and start early treatment with immunochemotherapy and bone marrow transplantation in primary and refractory cases. In this article, we review the clinical manifestations, pathology, diagnosis and treatment of these patients.


REFERENCES

  1. Scott R, Robb-Smith A. Histiocytic medullary reticulosis. Lancet. 1939;2:194-8.

  2. Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis. Arch Dis Child. 1952;27:519-25.

  3. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286:1957-9.

  4. Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991;80:428-35.

  5. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115:461-73.

  6. Zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14:827-34.

  7. Allen M, De Fusco C, Legrand F, et al. Familial hemophagocytic lymphohistiocytosis: how late can the onset be? Haematologica. 2001;86:499-503.

  8. Janka GE, Imashuku S, Elinder G, et al. Infection and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12:435-44.

  9. Janka GE. Familial hemophagocytic lymphohistiocytosis. European J Pediatrics. 1983;140:221-30.

  10. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis. 2000;6:601-8.

  11. Falini B, Pileri S, De Solas I, et al. Peripheral T cell lymphoma associated with hemophagocytic syndrome. Blood. 1990;75(2):434-4.

  12. Brodkin DE, Hobohm DW, Nigam R. Nasal-type NK/T-cell lymphoma presenting as hemophagocytic syndrome in an 11-year-old Mexican boy. J Pediatr Hematol Oncol. 2008;30(12):938-40.

  13. Petterson TE, Bosco AA, Cohn RJ. Aggressive natural killer cell leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50(3):654-7.

  14. Myers TJ, Kessimian N, Schwartz S. Mediastinal germ cell tumor associated with the hemophagocytic syndrome. Ann Intern Med. 1988;109(6):504-5.

  15. Lackner H, Urban C, Sovinz P, Benesch M, Moser A, Schwinger W. Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children. Haematologica. 2008;93(2):291-4.

  16. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421-6.

  17. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(3):965-71.

  18. Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655-64.

  19. Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89:4100-3.

  20. Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmunity Reviews. 2004;3:69-75.

  21. Tang YM, Xu XJ. Advances in hemophagocytic lymphohistiocytosis: pathogenesis, early diagnosis/differential diagnosis, and treatment. The Scient World J. 2011;11:697-708.

  22. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncology. 1991;18:29-33.

  23. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood Cancer. 2007;48:124-31.

  24. Jordan M, Allen C, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118:4041-52.

  25. Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis. 2003;36(3):306-12.

  26. Morrell DS, Pepping MA, Scott JP, Esterly NB, Drolet BA. Cutaneous manifestations of hemophagocytic lymphohistiocytosis. Arch Dermatol. 2002;138(9):1208-12.

  27. Thompson PA, Allen CE, Horton T, Jones JY, Vinks AA, McClain KL. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009;52(5): 621-5.

  28. Ouachee-Chardin M, Elie C, De Saint BG, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 2006;117(4):e743-50.

  29. Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol. 2006;81(1):59-61.

  30. Olin RL, Nichols KE, Naghashpour M, et al. Successful use of the anti- CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol. 2008;83(9):747-9.

  31. Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol. 2010;7(7):415-20.

  32. Tomaske M, Amon O, Bosk A, Handgretinger R, Schneider EM, Niethammer D. Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 2002;38(2):141-2.

  33. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101-9.

  34. Horne A, Janka G, Maarten ER, et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol. 2005;129(5):622-30.

  35. Filipovich A, McCLain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16 Suppl:82-9.

  36. Cooper N, Rao K, Gilmour K, et al. Stem cell transplantation with reduced- intensity conditioning for hemophagocytic lymphohistiocytosis. Blood. 2006;107(3):1233-6.

  37. Marsh RA, Vaughn G, Kim MO, et al. Reduced intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116(26):5824-31.

  38. Niedt GW, Schinella RA. Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. Arch Pathol Lab Med. 1985;109: 727-34.

  39. Fardet L, Lambotte O, Martínez V, et al. Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. AIDS. 2010;24:1299-306.

  40. Gotoh M, Matsuda J, Gohchi K, Sanaka T, Kawasugi K. Successful recovery from human immunodeficiency virus (HIV)-associated haemophagocytic syndrome treated with highly active anti-retroviral therapy in a patient with HIV infection. Br J Haematol. 2001;112:1090.

  41. Rouphael N, Talati N, Vaughan C, et al. Infections associated with haemophagocytic syndrome. Lancet Infect Dis. 2007;7:814-22.




2020     |     www.medigraphic.com